Minimizing the Impact of Drug-Resistant Streptococcus pneumoniae (DRSP)

摘要: Emergence of drug-resistant Streptococcus pneumoniae (DRSP) presents a challenge to the medical and public health communities since magnitude problem is not known, clinical impact DRSP infections well described, national vaccination rates are low, antimicrobial drugs often used excessively inappropriately. To address DRSP, working group sponsored by Centers for Disease Control Prevention was formed in June 1994 consisting practitioners, care providers, laboratorians representing state federal agencies various professional organizations. Through periodic open meetings, has developed strategy surveillance, investigation, prevention, control due DRSP. The focuses on (1) implementing an electronic laboratory-based surveillance (ELBS) system reporting invasive providing clinically relevant feedback clinicians, (2) identifying risk factors outcomes infection, (3) increasing pneumococcal vaccination, (4) promoting judicious drug use. Data received through ELBS will be make timely estimates community-specific prevalence pneumococci. National, regional, local trends made available providers clinicians promote optimal use increased targeted areas. Once operation, network adaptable other diseases, improving comprehensiveness timeliness surveillance. intended outcome reduce complications such as long-term sequelae expenditures, morbidity, mortality. ( JAMA . 1996;275:206-209)